Harlan Baird Radford Sells 87,064 Shares of Allakos Inc. (NASDAQ:ALLK) Stock

Allakos Inc. (NASDAQ:ALLK) CFO Harlan Baird Radford sold 87,064 shares of the company’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $1.01, for a total transaction of $87,934.64. Following the completion of the sale, the chief financial officer now directly owns 204,390 shares of the company’s stock, valued at $206,433.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Allakos Stock Performance

Shares of Allakos stock opened at $0.76 on Thursday. The company has a market capitalization of $67.29 million, a PE ratio of -0.31 and a beta of 0.88. The company has a 50-day simple moving average of $1.19 and a two-hundred day simple moving average of $1.47. Allakos Inc. has a one year low of $0.76 and a one year high of $5.64.

Allakos (NASDAQ:ALLK) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.09). On average, equities analysts predict that Allakos Inc. will post -1.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Allakos

Several hedge funds have recently modified their holdings of ALLK. Sectoral Asset Management Inc. increased its holdings in shares of Allakos by 77.3% during the third quarter. Sectoral Asset Management Inc. now owns 770,132 shares of the company’s stock valued at $1,748,000 after acquiring an additional 335,822 shares in the last quarter. Redmile Group LLC increased its holdings in shares of Allakos by 81.1% during the third quarter. Redmile Group LLC now owns 4,135,061 shares of the company’s stock valued at $9,387,000 after acquiring an additional 1,851,467 shares in the last quarter. Aristides Capital LLC acquired a new position in shares of Allakos during the fourth quarter valued at about $153,000. Pennant Investors LP acquired a new position in shares of Allakos during the fourth quarter valued at about $508,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Allakos by 1,041.1% during the first quarter. BNP Paribas Financial Markets now owns 205,663 shares of the company’s stock valued at $259,000 after acquiring an additional 187,640 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ALLK. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Allakos in a research note on Thursday, June 20th. JMP Securities reiterated a “market outperform” rating and issued a $3.00 target price on shares of Allakos in a report on Wednesday, June 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $1.83.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.